রোগ প্রতিরোধ ক্ষমতা পুনরুজ্জীবিত করে এমন বার্ধক্যবিরোধী ওষুধের পরীক্ষা সফল হয়েছে: বেশিরভাগ মধ্যবয়সী প্রাপ্তবয়স্করা রোগ প্রতিরোধ ক্ষমতাকে পুনরুজ্জীবিত করার জন্য একটি স্বল্পমেয়াদী চিকিত্সার দ্বারা উপকৃত হতে পারে এবং বয়সের সাথে ক্ষয়প্রাপ্ত অঙ্গগুলি, গবেষকরা বলছেন
বিজ্ঞানীরা একটি ক্লিনিকাল ট্রায়ালের সাফল্যকে স্বাগত জানিয়েছেন যা দেখেছে যে পরীক্ষামূলক অ্যান্টি-এজিং ওষুধগুলি তাদের ইমিউন সিস্টেমকে পুনরুজ্জীবিত করে সম্ভাব্য মারাত্মক শ্বাসযন্ত্রের সংক্রমণ থেকে বয়স্ক ব্যক্তিদের রক্ষা করতে পারে।.
বয়স্ক মানুষ জড়িত একটি বিচারে 65 এবং উপর, those who received a combination therapy of two anti-ageing compounds reported nearly half the number of infections over the following year as a control group who received only placebos.
People who took the two anti-ageing compounds as part of an experimental trial picked up considerably fewer infections over the following of a year, indicating improved immune system function. আলোকচিত্র: Viacheslav Lakobchuk/Alamy
The experimental drugs, known as mTOR inhibitors, also appeared to boost people’s responses to the flu vaccine, with tests revealing 20% more flu-fighting antibodies in the blood a month after the vaccination was given.
The findings are a milestone for researchers who believe that the best way to tackle diseases of old age may be to design new drugs that combat the ageing process itself.
“Immune function was just one of the things that got better,” said Joan Mannick, who worked on the trial at Novartis Institutes for Biomedical Research in Massachusetts. The researchers now have plans to test the drugs on other age-related conditions, such as neurodegenerative diseases.
“This is an extremely important and exciting study,” said Matt Kaeberlein, director of the Healthy Aging and Longevity Research Institute at the University of Washington, who was not involved in the study. The mTOR inhibitors “appear to broadly rejuvenate immune function in healthy elderly people," সে যুক্ত করেছিল. “I think this study raises the real possibility that most middle-aged adults could benefit from short-term treatments with mTOR inhibitors.”
The drugs work by blocking a cascade of events in the body that starts with the so-called “mechanistic target of rapamycin”, or mTOR. This is one of a group of proteins involved in the ageing process. Tests in mice have shown that experimental mTOR inhibitors can extend lifespan and revitalise the immune system and organs which deteriorate in old age.
The six week trial investigated the effects of two different mTOR inhibitors. দ্য 264 volunteers who took part received one or both of the drugs, or joined a control group that was given only placebos. All were then monitored for a year to see how their immune systems reacted, and how many respiratory infections they picked up. Those who had low doses of both drugs reported an average of 1.49 infections per year, সঙ্গে তুলনা 2.41 in the placebo group.
As people grow older, their immune systems weaken and they become increasingly vulnerable to infections and less able to generate the strong responses that vaccinations need to trigger to work well.
If drugs can be found that boost the immune systems of older people, they could help to protect the whole population from infections. “In the future, a larger percentage of our population is going to be older,” said Deborah Dunn-Walters, a professor of immunology at the University of Surrey who was not involved in the study. “If older people don’t respond well to vaccinations, then there will be more and more people that aren’t protected and who can potentially pass on infections to others in the population.”
“It is promising for the future that you can actually give these drugs at a very low dose which is not toxic and still seems to have a significant effect in protecting older people,” she added. Respiratory tract infections are one of the leading causes of death in older people and are largely responsible for the extreme burden on the NHS in the winter months.
Mannick, who is now chief medical officer at a Boston-based company called resTORbio, found that the drugs boosted immune responses that specifically target viruses. Details of the trial are published in the journal Science Translational Medicine.
The next stage of the research will look at whether the drugs work better in some groups of older people than others, for example the over-85s or those with conditions such as asthma, diabetes or heart failure.
“We hope we can keep everybody healthier and with a better quality of life as they grow older,” Mannick said.
উৎস: www.theguardian.com, by Layal Liverpool